Joe Nolan, a former Marathon Pharmaceuticals executive with 30 years of experience in the industry, will begin leading the division immediately.
Prior to his appointment, Nolan was chief commercial officer and senior vice president of Marathon, a company that focuses on rare disease treatment, and chief commercial officer at Lundbeck, Inc., a pharmaceutical company that specializes in brain diseases.
Dohmen Chief Executive Officer Cynthia LaConte began a national search for an executive with experience commercializing rare disease treatments to lead Dohmen Life Science Services in 2015.
“Joe’s leadership experience within rare disease not only brings incredible expertise to our clients, but his patient-centric perspective makes him an ideal cultural match to lead our next phase of growth,” LaConte said in a statement.
Dohmen Life Science Services assists biopharma and medical device companies by helping them navigate regulatory requirements, commercialize products, manage daily operations and center care around patients with rare diseases.
“I’ve built my career on the belief that patients come first,” Nolan said. “But I also understand the challenges life science companies face in trying to get their drug or device into a patient’s hands.”
Prior to working for Marathon and Lundbeck, Nolan held leadership positions at Takeda Pharmaceuticals, Abbott Laboratories/Hospira, TAP Pharmaceuticals, Schering-Plough and Walgreens.